Cas no 68892-41-1 (5'-O-DMT-N2-ibu-dG)
5'-O-DMT-N2-ibu-dG Chemical and Physical Properties
Names and Identifiers
-
- N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine
- 5'-O-(4,4'-Dimethoxytrityl)-N2-isobutyryl-2'-deoxyguanosine
- IBU-DMT-DEOXYGUANOSINE
- N-[9-[(2R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-6-oxo-3H-purin-2-yl]-2-methylpropanamide
- 5'-O-Dimethoxytrityl-N-isobutyryl-deoxyguanosine
- N2-Isobutyryl-5′-O-(4,4′-diMethoxytrityl)-2′-deoxyguanosine
- iBu-DMT-dG
- DMT-N-IB-DG
- 2'-Deoxy-5'-O-DMT-N2-isobutyrylguanosine
- Guanosine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-N-(2-methyl-1-oxopropyl)-
- Guanosine, 5'-O-(bis(4-methoxyphenyl)phenylmethyl)-2'-deoxy-N-(2-methyl-1-oxopropyl)-
- KSC912C7F
- RMQXDNUKLIDXOS-ZGIBFIJWSA-N
- 5'-O-[bis(4-methoxyphenyl)benzyl]-2'-deoxy-N-(2-methyl-1-oxopropyl)guanosine
- 5'-O-(Bis(4-methoxyphenyl)benzyl)-2'-deoxy-N-(2-methyl-1-oxopropyl)
- 5'-O-DMT-N2-ibu-dG
- MFCD00010059
- NS00036739
- 5'-O-DMT-N2-Isobutyryl-2'-Deoxyguanosine
- SCHEMBL2281663
- DS-14582
- DTXSID1074965
- BP-58861
- HY-W010702
- CS-W011418
- C35H37N5O7
- PD131006
- AKOS040758294
- EINECS 272-615-4
- N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine, ~98%
- A836283
- AKOS015837181
- I0697
- N-[9-[(2R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-6-oxo-1H-purin-2-yl]-2-methylpropanamide
- N-(9-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
- AKOS015895625
- 68892-41-1
- 5'-O-(Bis(4-methoxyphenyl)benzyl)-2'-deoxy-N-(2-methyl-1-oxopropyl)guanosine
- N-{9-[(2R,4S,5R)-5-{[BIS(4-METHOXYPHENYL)(PHENYL)METHOXY]METHYL}-4-HYDROXYOXOLAN-2-YL]-6-OXO-1H-PURIN-2-YL}-2-METHYLPROPANAMIDE
-
- MDL： MFCD00010059
- Inchi： 1S/C35H37N5O7/c1-21(2)32(42)38-34-37-31-30(33(43)39-34)36-20-40(31)29-18-27(41)28(47-29)19-46-35(22-8-6-5-7-9-22,23-10-14-25(44-3)15-11-23)24-12-16-26(45-4)17-13-24/h5-17,20-21,27-29,41H,18-19H2,1-4H3,(H2,37,38,39,42,43)/t27-,28+,29+/m0/s1
- InChI Key： RMQXDNUKLIDXOS-ZGIBFIJWSA-N
- SMILES： O1[C@H](C[C@@H]([C@H]1COC(C1C=CC=CC=1)(C1C=CC(=CC=1)OC)C1C=CC(=CC=1)OC)O)N1C=NC2C(NC(NC(C(C)C)=O)=NC1=2)=O
Computed Properties
- Exact Mass: 639.26900
- Monoisotopic Mass: 639.26929854g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 9
- Heavy Atom Count: 47
- Rotatable Bond Count: 11
- Complexity: 1080
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 3
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 146
- Surface Charge: 0
- Tautomer Count: 22
- XLogP3: nothing
Experimental Properties
- Color/Form: White powder
- Density: 1.2353 (rough estimate)
- Melting Point: 155°C(dec.)(lit.)
- Boiling Point: 671.92°C (rough estimate)
- Flash Point: No data available
- Refractive Index: 1.7500 (estimate)
- PSA: 149.82000
- LogP: 4.46140
- Solubility: Not determined
5'-O-DMT-N2-ibu-dG Security Information
- Signal Word：warning
- Hazard Statement： H302
-
Warning Statement：
P264Thoroughly clean after treatment
P280Wear protective gloves/Wear protective clothing/Wear protective goggles/Wear a protective mask
P305If it enters the eyes
P351Rinse carefully with water for a few minutes
P338Remove the contact lens(If any)And easy to operate,Continue flushing
P337If eye irritation persists
P313Obtain medical advice/care - WGK Germany：3
- Safety Instruction： S22-S24/25
- FLUKA BRAND F CODES：1-3-10
- Safety Term：S22;S24/25
- Storage Condition：Storage temperature: -20 ° C
5'-O-DMT-N2-ibu-dG Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-W010702-500mg |
5'-O-DMT-N2-ibu-dG |
68892-41-1 | ≥98.0% | 500mg |
￥500 | 2023-08-31 | |
| TRC | I780398-10mg |
N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine |
68892-41-1 | 10mg |
45.00 | 2021-08-04 | ||
| TRC | I780398-50mg |
N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine |
68892-41-1 | 50mg |
60.00 | 2021-08-04 | ||
| TRC | I780398-100mg |
N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine |
68892-41-1 | 100mg |
75.00 | 2021-08-04 | ||
| Chemenu | CM191787-10g |
N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine |
68892-41-1 | 95% | 10g |
$56 | 2024-07-24 | |
| Chemenu | CM191787-25g |
N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine |
68892-41-1 | 95% | 25g |
$140 | 2024-07-24 | |
| Chemenu | CM191787-100g |
N2-Isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine |
68892-41-1 | 95% | 100g |
$560 | 2024-07-24 | |
| SHANG HAI SHAO YUAN SHI JI Co., Ltd. | SY076881-1g |
N2-Isobutyryl-5’-O-(4,4’-dimethoxytrityl)-2’-deoxyguanosine |
68892-41-1 | ≥95% | 1g |
￥40.00 | 2025-04-13 | |
| SHANG HAI SHAO YUAN SHI JI Co., Ltd. | SY076881-5g |
N2-Isobutyryl-5’-O-(4,4’-dimethoxytrityl)-2’-deoxyguanosine |
68892-41-1 | ≥95% | 5g |
￥104.00 | 2025-04-13 | |
| SHANG HAI SHAO YUAN SHI JI Co., Ltd. | SY076881-10g |
N2-Isobutyryl-5’-O-(4,4’-dimethoxytrityl)-2’-deoxyguanosine |
68892-41-1 | ≥95% | 10g |
￥206.00 | 2025-04-13 |
5'-O-DMT-N2-ibu-dG Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
5'-O-DMT-N2-ibu-dG Related Literature
-
Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
-
Jason Wan Lab Chip, 2020,20, 4528-4538
-
Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
-
Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
-
Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
Additional information on 5'-O-DMT-N2-ibu-dG
Recent Advances in the Study of 5'-O-DMT-N2-ibu-dG and Its Chemical Properties
The compound 5'-O-DMT-N2-ibu-dG, with the CAS number 68892-41-1, has garnered significant attention in the field of chemical biology and pharmaceutical research. This modified deoxyguanosine derivative plays a crucial role in oligonucleotide synthesis, particularly in the development of therapeutic nucleic acids. Recent studies have focused on optimizing its synthesis, understanding its stability, and exploring its applications in drug discovery and development.
One of the key advancements in the study of 5'-O-DMT-N2-ibu-dG is the refinement of its synthetic pathways. Researchers have developed more efficient methods for introducing the isobutyryl (ibu) and dimethoxytrityl (DMT) protecting groups, which are essential for the compound's stability during oligonucleotide synthesis. These improvements have not only increased the yield but also reduced the formation of by-products, making the process more cost-effective and scalable for industrial applications.
In addition to synthetic improvements, recent research has delved into the compound's biochemical properties. Studies have shown that 5'-O-DMT-N2-ibu-dG exhibits enhanced resistance to nuclease degradation compared to its unmodified counterparts. This property is particularly valuable in the design of antisense oligonucleotides and siRNA therapeutics, where stability in biological environments is a critical factor for efficacy.
Another area of focus has been the application of 5'-O-DMT-N2-ibu-dG in the development of novel therapeutics. For instance, researchers have incorporated this modified nucleoside into oligonucleotides targeting specific mRNA sequences associated with genetic disorders. Preliminary results indicate that these modified oligonucleotides exhibit improved binding affinity and specificity, leading to enhanced therapeutic outcomes in preclinical models.
Furthermore, the compound's role in the emerging field of gene editing has been explored. By incorporating 5'-O-DMT-N2-ibu-dG into guide RNAs for CRISPR-Cas9 systems, scientists have observed increased stability and reduced off-target effects. This finding opens new avenues for precision medicine and the treatment of complex genetic diseases.
Despite these promising developments, challenges remain. The long-term safety and pharmacokinetic profiles of oligonucleotides containing 5'-O-DMT-N2-ibu-dG need further investigation. Additionally, the scalability of its synthesis for large-scale therapeutic production requires optimization to meet the growing demand for nucleic acid-based therapies.
In conclusion, the study of 5'-O-DMT-N2-ibu-dG (CAS: 68892-41-1) continues to be a vibrant area of research with significant implications for the pharmaceutical industry. Advances in its synthesis, stability, and therapeutic applications underscore its potential as a key building block in the development of next-generation nucleic acid therapeutics. Future research should focus on addressing the remaining challenges to fully realize its clinical potential.
68892-41-1 (5'-O-DMT-N2-ibu-dG) Related Products
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
